MedWatch

Analyst on Novo stock: The risk of disappointments is bigger than the chance of surprises

2021 has been a golden year for Novo Nordisk, says a Jyske Bank analyst, whose recommendation for Novo stock is "hold" because of noteworthy price increases.

Photo: Jyske Bank/PR

Danish bank Jyske Bank is raising its share price target for Novo Nordisk stock to DKK 780 (USD 117.6) from DKK 670 (USD 100.1), according to an analysis the bank has conducted.

In connection with this, the bank maintains its recommendation to "hold." The huge share price increase this year has meant that the bank cannot justify the recommendation "buy," despite the stock's upward momentum.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs